Discovery Evolution: STRT Invest backs digital biologics discovery platform
Discovery Evolution has secured a strategic investment from STRT Invest to accelerate development of its AI-driven RedQueen platform for biologics discovery and advance its internal therapeutic pipeline.
Vienna-based biotechnology company Discovery Evolution has announced a strategic investment from STRT Invest, one of Central and Eastern Europe’s leading early-stage technology investors. Financial terms of the investment were not disclosed. The partnership aims to support the development of globally competitive deep-tech companies originating from Central and Eastern Europe. :contentReference[oaicite:0]{index=0}
The investment will be used to further develop Discovery Evolution’s proprietary RedQueen platform and initiate the company’s internal therapeutic discovery pipeline. RedQueen combines digital evolution, computational biophysics and artificial intelligence to discover therapeutic antibodies against challenging drug targets, particularly G protein-coupled receptors (GPCRs). :contentReference[oaicite:1]{index=1}
According to the company, RedQueen shifts much of the antibody discovery process from the laboratory into a computational environment, accelerating candidate generation while reducing experimental costs. Since its founding, Discovery Evolution has experimentally validated antibodies identified through the platform and has expanded its capabilities in developing therapeutics targeting GPCRs and other complex membrane proteins. The company has also secured competitive non-dilutive funding from the Austrian Research Promotion Agency (FFG) and Austria Wirtschaftsservice (aws). :contentReference[oaicite:2]{index=2}
“We are delighted to welcome STRT Invest as a strategic partner,” said Harold P. de Vladár, Founder and CEO of Discovery Evolution. “Beyond capital, STRT brings entrepreneurial experience, an exceptional network, and a long-term commitment to helping technology companies scale internationally.” :contentReference[oaicite:3]{index=3}
Peter Langmar, Investment Director of STRT Invest, said the company represents the type of deep-tech innovation with global potential the investor seeks in Central and Eastern Europe. He highlighted the combination of AI and digital modelling as a way to transform biologics discovery by reducing both development time and costs. :contentReference[oaicite:4]{index=4}
Kontakt
Discovery Evolution
Harold P. de Vladár
Founder & CEO
E-Mail: office@discovery-evolution.com
STRT Invest
Istvan Toth
Public and Investor Relations
E-Mail: istvan.toth@strt.hu